Eliquis Regulatory Post Marketing Surveillance (rPMS)

Bristol-Myers Squibb100 enrolled

Overview

The objective of this regulatory Post-Marketing Surveillance in Korea is to reconfirm the clinical usefulness of Eliquis through collecting, reviewing, identifying and verifying the safety and effectiveness information about Eliquis in general practice

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Venous Thromboembolism

Interventions

ApixabanDRUG

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Signed data release * Patients undergoing elective total hip replacement arthroplasty or elective total knee replacement arthroplasty Exclusion Criteria: * Being treated for an indication not approved for the use of Eliquis® in Korea * Is contraindicated for the use of Eliquis® as described in the Korean label

Locations (1)

Local Institution

Seoul, South Korea

Outcomes

Primary Outcomes

Number of Adverse Events (AEs) and serious AEs

Time frame: Up to 30 days after last study drug dose

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.